Expert Opinion on Pharmacotherapy

Article	Citations
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	48
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	42
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	40
Oral anticoagulation therapy in the setting of liver disease	37
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	37
Current treatment options for Mycobacterium marinum cutaneous infections	36
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	35
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	32
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	29
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	28
The pharmacological treatment and management of hyperhidrosis	26
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	26
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	23
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	23
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	22
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	22
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	21
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	20
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	20
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	20
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	19
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	19
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	19
Momelotinib in myelofibrosis	18
Selecting optimal therapy in systemic mastocytosis: current state and future directions	18

Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	17
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	17
Correction	17
How useful is chemotherapy for atypical and anaplastic meningiomas?	17
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	16
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials	16
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	16
Zanubrutinib for the treatment of chronic lymphocytic leukemia	16
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective	16
Pharmacologic management of ET: established therapies and emerging agents	16
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	15
Correction	15
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	15
Current advances in colorectal cancer treatment: a review of recent clinical trials	15
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	15
Rise and fall of decongestants in treating nasal congestion related diseases	15
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	15
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	14
An update on current pharmacotherapy for vulvar cancer	14
Current pharmacological solutions for Behçet’s syndrome	14
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	14
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	14
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs	14
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	14
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	14
Treating pediatric aggressive behaviors and comorbid conditions	14
Approved medications for opioid use disorder : current update	14
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	13
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	13
Upadacitinib in Crohn’s disease	13
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	13
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	13
Tirzepatide for overweight and obesity management	13
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	13
Recent advances in the treatment of FGFR-altered cholangiocarcinoma	13
Current advancements in pharmacotherapy for cancer cachexia	13
The role of pharmacotherapy in the treatment of endometriosis: an update	12
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	12
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	12
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	12
Recent progress in the use of pharmacotherapy for endometrial cancer	12
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	12
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	12
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	12
Simnotrelvir as a potential treatment for COVID-19	12
Use of glucagon-like polypeptide 2 analogs for intestinal failure	11
Drug treatment strategies for eosinophilic esophagitis in adults	11
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	11
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	11
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	11

An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	11
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	11
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	11
Modern pharmacotherapy guidance for treating alcohol use disorders	11
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	10
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	10
Advances with androgen deprivation therapy for prostate cancer	10
Migraine in multiple sclerosis patients: potential links and treatment approach	10
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	10
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	10
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	10
Evidence-based prescribing of medications for ADHD: where are we in 2023?	10
Antiproliferative therapies in pulmonary arterial hypertension	10
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	10
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	10
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	10
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	10
Pharmacological management of pituitary adenomas – what is new on the horizon?	10
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	10
Current status of intracavernosal injection therapy in erectile dysfunction	10
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	10
An overview of emergency pharmacotherapy for priapism	10
Reassessing the role of aspirin in patients with coronary artery disease	9
Advances in the pharmacotherapeutic management of refractory peptic ulcers	9
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	9
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	9
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	9
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	9
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	9
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	9
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	9
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	9
The management of cardiovascular disease risk in patients with rheumatoid arthritis	9
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	9
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	9
The relationship between cognition and the pharmacotherapy of depression	9
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	9
Pharmaceutical advances in the treatment of gastric adenocarcinoma	9
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	9
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	9
Recently approved and emerging drug options for migraine prophylaxis	9
Risk management of medication errors: a novel conceptual framework	8
Upadacitinib in Crohn’s disease: needs more insight	8
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	8
Addressing the long-term risks of administering antenatal steroids	8
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	8
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	8
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	8
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	8
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	8
Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease	8
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	8
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	8
Pharmacological treatment for children with constipation: present and future	8
Evaluating upadacitinib for the treatment of psoriatic arthritis	8
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	8
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	8
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	8
Effective risk reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections	8
An update on antifungal resistance in dermatophytosis	8
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	8
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	8
Guidance for the pharmacological management of COVID-19 in the emergency setting	8
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	8
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	8
An update on the pharmacotherapy of gout	8
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	8
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	8
An update on the pharmacological management of acne vulgaris: the state of the art	8
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	8
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	8
Pharmacological management of migraine: current strategies and future directions	8
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	8
Promising therapies for the treatment of acromegaly	8
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	8
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	8
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	8
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	7
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	7
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	7

Pharmacotherapy for bipolar disorder in adults with high-functioning autism	7
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	7
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	7
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	7
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	7
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	7
The pharmacological management of alcohol-related cirrhosis: what’s new?	7
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	7
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	7
New and emerging drugs for the treatment of invasive fungal infections	7
State-of-the-art and emerging antivirals for chronic hepatitis B infection	7
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	7
Glasdegib for the treatment of acute myeloid leukemia	7
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	7
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	7
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	7
Polypharmacology of carbonic anhydrase inhibitors and activators	7
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	7
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	7
Advances in pharmacotherapy for bronchiectasis in adults	7
Advances in the pharmacological management of acute myeloid leukemia in adults	7
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	7
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	7
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	7
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	7
The pharmacological management of treatment-resistant depression: what does the future hold?	7
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	7
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	7
Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis	7
Pharmacological management of heart failure: a patient-centred approach	7
Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia	7
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)	6
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	6
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	6
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	6
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	6
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	6
An update on inclisiran for the treatment of elevated LDL cholesterol	6
How far are we from an approved drug for nonalcoholic steatohepatitis?	6
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	6
Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence	6
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	6
Perspectives on the currently available pharmacotherapy for wet macular degeneration	6
Investigating cefepime/taniborbactam for the treatment of complicated urinary tract infections	6
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	6
An evaluation of the available pharmacotherapy for the treatment of hirsutism	6
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	6
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	6
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	6
Liposomal drug formulations for treatment of hematological malignancies	6
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	6
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	6
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes	6
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?	6
Efficacy and safety of pitolisant in children above 6 years with narcolepsy	6
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature	6
Current factor IX replacement options for hemophilia B and the challenges ahead	6
Post-surgical pain: evolving drug treatments and challenges	6
Novel pharmacotherapy for drug-induced immune hemolytic anemia	6
Montelukast as a potential treatment for COVID-19	6
Paxlovid as a potential treatment for long COVID	6
Valbenazine for the treatment of chorea associated with Huntington’s disease	6
The latest advances in the pharmacological management of endometriosis	6
An update on the pharmacotherapy of osteoporosis	6
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	6
Pharmacotherapy for post-stroke aphasia: what are the options?	5
New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview	5
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy	5
Current chemotherapeutic options for the treatment of gestational trophoblastic disease	5
Current and emerging pharmacotherapy for menstrual migraine: a narrative review	5
Developments in pharmacotherapy for the preservation of ovarian function during cancer treatment	5
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia	5
Pharmaceutical management of sexual dysfunction in men on antidepressant therapy	5
Has the utilization of serotonin receptor antagonism made an impact on schizophrenia treatment?	5
The current role of maribavir for treatment of cytomegalovirus in transplant recipients	5
Selecting optimal therapy for chronic neutrophilic leukemia: new prospects based on genetic and molecular makeup	5
Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy	5
Response to: “the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19”	5
Managing the neuroinflammatory pain of endometriosis in light of chronic pelvic pain	5
Advances in drug treatments for mesothelioma	5
Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials	5
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia	5
The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration	5
Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors	5
Immunosuppression in uterus transplantation: from transplant to delivery	5
An update on pharmacotherapies for colorectal cancer: 2023 and beyond	5
An update on the pharmacological management of acute respiratory distress syndrome	5
Advances in small molecule maintenance therapies for high-grade serous ovarian cancer	5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia	5
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential	5
Talazoparib for the treatment of prostate cancer	5
Complicated urinary tract infections: an update of new and developing antibiotics	5
Optimizing pharmacological management of the febrile child	5
Should we discontinue RAS-inhibitor therapy in patients with advanced CKD?	5
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review	5